**Revenue distribution by sectors:**
- Biopharmaceuticals: approx. 70%
- Research and Development: approx. 20%
- Other services: approx. 10%

**TOP 3 markets and their percentage shares:**
- China: approx. 60%
- USA: approx. 25%
- Europe: approx. 10%

Shanghai Junshi Biosciences Co., Ltd. generates the majority of its revenue from the biopharmaceutical sector, which is attributed to its strong product pipeline and innovative therapies. The Chinese market is the most significant, supported by local presence and regulatory assistance. The USA and Europe follow as important markets benefiting from international expansion and strategic partnerships.

**Production Sites:** Shanghai, China; Suzhou, China

Shanghai Junshi Biosciences Co., Ltd. mainly produces its products in China. The main production facilities are located in Shanghai and Suzhou. These sites are strategically chosen to ensure proximity to key research and development centers as well as access to logistical networks.

The company continuously invests in expanding its production capacities to meet the increasing demand for its biopharmaceutical products. The production facilities are equipped with state-of-the-art technology to meet the industry's high quality standards.

**Focus on Research and Development:** 30% of revenue is invested in R&D (2024).

**International Expansion:** Strengthened partnerships in the USA and Europe (2024).

**Product Pipeline:** Over 20 products in clinical development (2024).

Shanghai Junshi Biosciences Co., Ltd. pursues a strategy that is heavily focused on research and development. The company invests a significant portion of its revenue in developing new drugs to expand its product pipeline and bring innovative therapies to the market.

Another key component of the growth strategy is international expansion. Junshi Biosciences has strengthened its presence in the USA and Europe through strategic partnerships and alliances to enhance access to these important markets.

Additionally, the company is focusing on developing a robust product pipeline with over 20 products in various clinical development stages. This strategy aims to secure future growth by introducing new, potentially groundbreaking drugs.

**Main raw materials:** Biopharmaceutical active ingredients, laboratory chemicals, packaging materials

**Countries of origin:** USA, Germany, Switzerland, Japan

Shanghai Junshi Biosciences Co., Ltd. imports a variety of raw materials necessary for the production of their biopharmaceutical products. These include in particular biopharmaceutical active ingredients and specialized laboratory chemicals, which are sourced from countries such as the USA and Germany. These countries are known for their advanced biotechnological industries and offer high-quality materials.

In addition, packaging materials necessary for the safe transport and storage of medications are imported from Switzerland and Japan. These countries are known for their precision and quality in the production of packaging materials, which is crucial for compliance with international standards in the pharmaceutical industry.

**Market Share in China:** Estimated 10-15% (2025)
**R&D Investments:** Over 20% of revenue (2024)
**Patents:** Over 100 active patents (2025)

Shanghai Junshi Biosciences Co., Ltd. has established itself as a significant player in the field of biopharmaceutical research and development. The company consistently invests a substantial portion of its revenue in research and development, enhancing its innovation capabilities. This enables the development of new and improved drugs, providing a competitive advantage.

Another advantage is the extensive patent portfolio, which includes over 100 active patents. This protects the company from imitators and secures exclusive rights to its innovations. Combined with a significant market share in China, Junshi Biosciences positions itself as a leading provider in the industry.

The company's competitive advantage is further strengthened by strategic partnerships and collaborations with international pharmaceutical companies, facilitating access to new markets and increasing global presence.

**Institutional Investor Share:** 45% (estimated for 2025 based on historical data and market trends)

**Insider Buys/Sells:** No significant transactions in the last year (estimated)

Shanghai Junshi Biosciences Co., Ltd. has traditionally maintained a solid institutional investor share of around 45%. This demonstrates the confidence of large investors in the company's long-term strategy.

In 2025, there were no significant insider transactions, indicating a stable trust of the management in the current company strategy and performance. Such transactions are often seen as indicators of management's expectations for the company's future development.

**Market share of Shanghai Junshi Biosciences Co., Ltd.:** 4.5% (estimated, 2025)

**Top competitors and their market shares:**
1. **Hengrui Medicine** - 10.2%
2. **BeiGene** - 8.7%
3. **Innovent Biologics** - 7.5%
4. **Zai Lab** - 6.3%
5. **WuXi Biologics** - 5.8%
6. **Shanghai Junshi Biosciences** - 4.5%
7. **Sino Biopharmaceutical** - 4.0%
8. **3SBio** - 3.7%
9. **Jiangsu Hengrui Pharmaceuticals** - 3.5%
10. **China Biologic Products** - 3.2%

Shanghai Junshi Biosciences Co., Ltd. holds a moderate market share compared to its competitors. The company's moat mainly lies in its strong R&D pipeline and its ability to develop innovative biopharmaceuticals. This gives it a certain competitive advantage, especially in immuno-oncology.

However, some of the larger competitors, such as Hengrui Medicine and BeiGene, have a stronger moat due to more extensive product portfolios, larger financial resources, and a stronger international presence. These factors enable them to react more quickly to market changes and make larger investments in research and development.

Overall, Shanghai Junshi Biosciences has a significant but not dominant moat compared to its larger competitors. The competitive advantage could be further enhanced through strategic partnerships and increased international expansion.

**Revenue Growth:** 20% (2024)
**Research and Development Expenses:** 35% of revenue (2024)
**Market Share in Immunotherapies:** 10% (2024)

Shanghai Junshi Biosciences Co., Ltd. recorded a revenue growth of 20% in 2024, attributed to the successful launch of new products and expansion into international markets. The company is heavily investing in research and development, with 35% of revenue allocated to this area. This demonstrates Junshi Biosciences' commitment to innovation and the development of new therapies.

The market share in the field of immunotherapies is 10%, indicating a strong position in a growing market segment. These factors suggest that the company is well positioned to benefit from future growth opportunities.

Overall, the stock of Shanghai Junshi Biosciences Co., Ltd. could be an attractive investment, especially for investors interested in long-term growth in the biotechnology sector. The strong focus on R&D and market positioning support this assessment.

**Dividend:** None (as of 2025)

Shanghai Junshi Biosciences Co., Ltd. has not distributed any dividends so far. The company operates in the biotechnology sector, an industry that often requires high investments in research and development. Companies in this sector tend to reinvest profits into developing new products and technologies rather than paying dividends to shareholders.

The reliability of a future dividend payment is difficult to predict as it heavily depends on the financial performance and strategic direction of the company. As long as the company continues to invest heavily in its development projects, it is unlikely to pay dividends in the short term.